16.2 Dopamine Transporter and CYP2D6 Gene Effects on ADHD in the Methylphenidate and Atomoxetine Crossover Study

Abstract

Despite 25 years of ADHD pharmacogenetic studies, there are few reliable predictors to guide treatment. The dopamine transporter (DAT1) is a primary pharmacodynamic target for methylphenidate (MPH) with known genetic variation hypothesized to impact response, while CYP2D6 variation impacts atomoxetine (ATX) kinetics. We examined genetic variation in DAT1 and CYP2D6 with dose response in youth diagnosed with ADHD exposed to both medications.